Myriad Genetics CFO covers taxes with 549 shares

MYRIAD GENETICS INC Chief Financial Officer Benjamin Richard Wheeler had 549 shares of Common Stock withheld by the company to cover tax obligations tied to restricted stock unit vesting.

Accepted by SEC EDGAR 03/23/2026 - 04:22 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

MYRIAD GENETICS INC Chief Financial Officer Benjamin Richard Wheeler had 549 shares of Common Stock withheld by the company to cover tax obligations tied to restricted stock unit vesting. The withheld shares were valued at $4.58 per share, based on the closing price on March 20, 2026.

These shares were not sold in the open market but retained by the issuer to satisfy tax withholding requirements. After this tax-withholding disposition, Wheeler directly holds 298,509 shares of Myriad Genetics common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 549 shares

Exercise Price or Tax Liability 1 txn

Insider Wheeler Benjamin Richard

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	549	$4.58	$3K

Holdings After Transaction: Common Stock — 298,509 shares (Direct)

Footnotes (1)

1. F1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 20, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MYRIAD GENETICS (MYGN) report for its CFO?

MYRIAD GENETICS reported that CFO Benjamin Richard Wheeler had 549 shares withheld to cover tax obligations from restricted stock unit vesting. This was a tax-withholding disposition, not an open-market sale, and the shares were retained by the company.

How many MYRIAD GENETICS (MYGN) shares were involved in the CFO’s Form 4 filing?

The Form 4 shows 549 shares of MYRIAD GENETICS Common Stock were withheld. These shares covered tax withholding obligations related to previously granted restricted stock units that vested, rather than representing a voluntary purchase or sale in the market.

At what price were the MYRIAD GENETICS (MYGN) shares valued for the CFO’s tax withholding?

The 549 withheld shares were valued at $4.58 per share. The number of shares was determined using the closing price of MYRIAD GENETICS Common Stock on March 20, 2026, as disclosed in the filing footnote.

Did the MYRIAD GENETICS (MYGN) CFO sell shares on the open market in this Form 4?

No, the CFO did not sell shares on the open market. The 549 shares were withheld by MYRIAD GENETICS to satisfy tax withholding obligations from restricted stock unit vesting, a routine administrative transaction rather than a discretionary trade.

How many MYRIAD GENETICS (MYGN) shares does the CFO hold after this transaction?

Following the tax-withholding disposition, CFO Benjamin Richard Wheeler directly holds 298,509 shares of MYRIAD GENETICS Common Stock. This remaining position is reported in the Form 4 as the total shares beneficially owned after the transaction.

What does transaction code "F" mean in the MYRIAD GENETICS (MYGN) CFO Form 4?

Transaction code "F" indicates a tax-withholding disposition, where shares are delivered to the issuer to cover exercise price or tax liability. In this case, 549 shares were withheld to satisfy tax obligations on vested restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wheeler Benjamin Richard

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/22/2026		F		549(1)	D	$4.58	298,509	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 20, 2026.

Remarks:

	By: Justin Hunter For: Benjamin R. Wheeler	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)